ARMAN HEKMATI: Open Payments
NPI 1326080128 · LOS ANGELES, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,465 in 108 payments from 24 companies in 2025. Trend: 2023 $2,094 · 2024 $2,121 · 2025 $2,465
Food & beverage: $2,465
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 14 | $330 |
| AstraZeneca Pharmaceuticals LP | 12 | $294 |
| Bayer Healthcare Pharmaceuticals Inc. | 9 | $214 |
| Axsome Therapeutics, Inc. | 7 | $165 |
| GlaxoSmithKline, LLC. | 8 | $156 |
| Eisai Inc. | 7 | $149 |
| Lilly USA, LLC | 5 | $133 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $123 |
| Novo Nordisk Inc | 4 | $105 |
| Bausch Health US, LLC | 5 | $102 |
Products named: Kerendia, Auvelity, Leqembi, TRINTELLIX, TRELEGY ELLIPTA, Ozempic, WELLBUTRIN, REXULTI.
Industry payments across CA — which companies pay providers there.
